Expert: Berardino De Bari, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland

Questions:

1- Moderate hypofractionation is considered a standard of care in prostate radiotherapy. What is the state of the art in 2021 for extreme hypofractionation in prostate cancer?

2- What’s your point of view about the multidisciplinary approach to locally advanced prostate cancer?

3- Some very recent studies seems to close the neverending debate on adjuvant vs salvage radiotherapy. Could you summarize these findings?

4- Is there a role for local treatments in metastatic prostate cancer?

5- PSMA PET/CT is clearing changing the approach to prostate cancer. Could you summarize us how it can impact the therapeutic strategy for prostate cancer patients?